The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque

Neuropharmacology

Volumn 97, Issue , 2015, Pages 306-311

  Huot, Philippe ^a,b,d   Johnston, Tom H ^a   Fox, Susan H ^a,b   Newman Tancredi, Adrian ^c   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c NEUROLIXIS INC   (United States)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Dyskinesia; F15599; L DOPA; MPTP lesioned macaque; On time

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 CHLORO 4 FLUOROPHENYL [4 FLUORO 4-[[(5 METHYLPYRIMIDIN-2-YLMETHYL)AMINO]METHYL]PIPERIDIN 1 YL]METHANONE; BENSERAZIDE PLUS LEVODOPA; LEVODOPA; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; 3-CHLORO-4-FLUOROPHENYL-(4-FLUORO-4-(((5-METHYLPYRIMIDIN-2-YLMETHYL)AMINO)METHYL)PIPERIDIN-1-YL)METHANONE; ANTIPARKINSON AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN 1 AGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SELECTIVITY; DYSKINESIA; FEMALE; MACACA FASCICULARIS; MOTOR ACTIVITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; MPTP POISONING; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MOTOR ACTIVITY; MPTP POISONING; PIPERIDINES; PYRIMIDINES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX;

EID: 84933499711     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.05.033     Document Type: Article

References (52)

1. M.B. Assie, L. Bardin, A.L. Auclair, E. Carilla-Durand, R. Depoortere, W. Koek, M.S. Kleven, F. Colpaert, B. Vacher, and A. Newman-Tancredi F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity Int. J. Neuropsychopharmacol. 2010 1 14
2. M.B. Assie, and W. Koek Possible in vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats Br. J. Pharmacol. 119 1996 845 850
3. M.B. Assie, and W. Koek [(3)H]-8-OH-DPAT binding in the rat brain raphe area: involvement of 5-HT(1A) and non-5-HT(1A) receptors Br. J. Pharmacol. 130 2000 1348 1352
4. G.D. Bartoszyk, C. Van Amsterdam, H.E. Greiner, W. Rautenberg, H. Russ, and C.A. Seyfried Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile J. Neural Transm. 111 2004 113 126
5. E. Bezard, E. Tronci, E.Y. Pioli, Q. Li, G. Porras, A. Bjorklund, and M. Carta Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia Mov. Disord. 28 2013 1088 1096
6. F. Bibbiani, J.D. Oh, and T.N. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 2001 1829 1834
7. M. Carta, T. Carlsson, D. Kirik, and A. Bjorklund Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833
8. M.A. Cenci Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications Front. Neurol. 5 2014 242
9. L.J. Cornfield, G. Lambert, L.E. Arvidsson, C. Mellin, J. Vallgarda, U. Hacksell, and D.L. Nelson Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase Mol. Pharmacol. 39 1991 780 787
10. R. Depoortere, A.L. Auclair, L. Bardin, F.C. Colpaert, B. Vacher, and A. Newman-Tancredi F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists Eur. Neuropsychopharmacol. 20 2010 641 654
11. K.B. Dupre, C.Y. Ostock, K.L. Eskow Jaunarajs, T. Button, L.M. Savage, W. Wolf, and C. Bishop Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats Exp. Neurol. 229 2011 288 299
12. D.S. Dupuis, S. Tardif, T. Wurch, F.C. Colpaert, and P.J. Pauwels Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein Neuropharmacology 38 1999 1035 1041
13. S. Fahn The history of dopamine and levodopa in the treatment of Parkinson's disease Mov. Disord. 23 Suppl. 3 2008 S497 S508
14. S.H. Fox, T.H. Johnston, Q. Li, J. Brotchie, and E. Bezard A critique of available scales and presentation of the non-human primate dyskinesia rating scale Mov. Disord. 27 2012 1373 1378
15. C.G. Goetz, P. Damier, C. Hicking, E. Laska, T. Muller, C.W. Olanow, O. Rascol, and H. Russ Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov. Disord. 22 2007 179 186
16. L. Gregoire, P. Samadi, J. Graham, P.J. Bedard, G.D. Bartoszyk, and T. Di Paolo Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys Parkinsonism Relat. Disord. 15 2009 445 452
17. A. Hamik, D. Oksenberg, C. Fischette, and S.J. Peroutka Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites Biol. Psychiatry 28 1990 99 109
18. M.A. Hely, J.G. Morris, W.G. Reid, and R. Trafficante Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years Mov. Disord. 20 2005 190 199
19. P. Heusler, I. Rauly-Lestienne, A. Tourette, S. Tardif, M.C. Ailhaud, G. Croville, and D. Cussac Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist Eur. J. Pharmacol. 640 2010 8 14
20. A.J. Hughes, S.E. Daniel, L. Kilford, and A.J. Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J. Neurol. Neurosurg. Psychiatry 55 1992 181 184
21. A.J. Hughes, S.E. Daniel, and A.J. Lees Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease Neurology 57 2001 1497 1499
22. P. Huot, and J.M. Brotchie 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms Exp. Neurol. 231 2011 195 198
23. P. Huot, and S.H. Fox The serotonergic system in motor and non-motor manifestations of Parkinson's disease Exp. Brain Res. 230 2013 463 476
24. P. Huot, S.H. Fox, and J.M. Brotchie The serotonergic system in Parkinson's disease Prog. Neurobiol. 95 2011 163 212
25. P. Huot, S.H. Fox, A. Newman-Tancredi, and J.M. Brotchie Anatomically-selective 5-HT1A and 5-HT2A therapies for Parkinson's disease - an approach to reducing dyskinesia without exacerbating parkinsonism? J. Pharmacol. Exp. Ther. 339 2011 1 7
26. P. Huot, T.H. Johnston, J.B. Koprich, A. Aman, S.H. Fox, and J.M. Brotchie L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease J. Pharmacol. Exp. Ther. 342 2012 576 585
27. P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, and J.M. Brotchie L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease Neuropharmacology 63 2012 829 836
28. P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, and J.M. Brotchie The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease Pharmacol. Rev. 65 2013 171 222
29. P. Huot, T.H. Johnston, J.B. Koprich, L. Winkelmolen, S.H. Fox, and J.M. Brotchie Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque Neurobiol. Aging 33 2012 e209 219 207
30. P. Huot, T.H. Johnston, T. Snoeren, J.B. Koprich, M.P. Hill, S.H. Fox, and J.M. Brotchie Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque Eur. J. Neurosci. 37 2013 831 838
31. H. Iderberg, A.C. McCreary, M.A. Varney, M.A. Cenci, and A. Newman-Tancredi Activity of serotonin 5-HT receptor 'biased agonists' in rat models of Parkinson's disease and l-DOPA-induced dyskinesia Neuropharmacology 93C 2015 52 67
32. M.M. Iravani, K. Tayarani-Binazir, W.B. Chu, M.J. Jackson, and P. Jenner In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with- increased motor disability J. Pharmacol. Exp. Ther. 319 2006 1225 1234
33. T.H. Johnston, S.H. Fox, M.J. McIldowie, M.J. Piggott, and J.M. Brotchie Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease J. Pharmacol. Exp. Ther. 333 2010 865 873
34. T.H. Johnston, S.H. Fox, M.J. Piggott, J.M. Savola, and J.M. Brotchie The alpha adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates Mov. Disord. 25 2010 2084 2093
35. T.H. Johnston, P. Huot, S.H. Fox, J.B. Koprich, K.T. Szeliga, J.W. James, J.D. Graef, S.R. Letchworth, K.G. Jordan, M.P. Hill, and J.M. Brotchie TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque Neuropharmacology 73C 2013 337 347
36. K. Kannari, K. Kurahashi, M. Tomiyama, T. Maeda, A. Arai, M. Baba, T. Suda, and M. Matsunaga Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease No To Shinkei 54 2002 133 137
37. K. Kannari, H. Yamato, H. Shen, M. Tomiyama, T. Suda, and M. Matsunaga Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation J. Neurochem. 76 2001 1346 1353
38. T. Kenakin Functional selectivity and biased receptor signaling J. Pharmacol. Exp. Ther. 336 2011 296 302
39. J.B. Koprich, P. Huot, S.H. Fox, K. Jarvie, A.E. Lang, P. Seeman, and J.M. Brotchie The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques Prog. Neuropsychopharmacol. Biol. Psychiatry 43 2013 151 156
40. L. Llado-Pelfort, M.B. Assie, A. Newman-Tancredi, F. Artigas, and P. Celada Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors Br. J. Pharmacol. 160 2010 1929 1940
41. J.L. Maurel, J.M. Autin, P. Funes, A. Newman-Tancredi, F. Colpaert, and B. Vacher High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity J. Med. Chem. 50 2007 5024 5033
42. N. Nevalainen, S. Af Bjerken, M. Lundblad, G.A. Gerhardt, and I. Stromberg Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia J. Neurochem. 118 2011 12 23
43. A. Newman-Tancredi Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders Neuropsychiatry 1 2011 149 164
44. A. Newman-Tancredi, M.B. Assie, N. Leduc, A.M. Ormiere, N. Danty, and C. Cosi Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia Int. J. Neuropsychopharmacol. 8 2005 341 356
45. A. Newman-Tancredi, C. Conte, C. Chaput, L. Verriele, and M.J. Millan Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor: G-protein stoichiometry Neuropharmacology 36 1997 451 459
46. A. Newman-Tancredi, J.C. Martel, M.B. Assie, J. Buritova, E. Lauressergues, C. Cosi, P. Heusler, L. Bruins Slot, F.C. Colpaert, B. Vacher, and D. Cussac Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist Br. J. Pharmacol. 156 2009 338 353
47. NIH N. Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of Laboratory Animals 1996 U.S. Dept. of Health and Human Services, Public Health Service Bethesda, Md
48. M.F. Piercey, M.W. Smith, and J.T. Lum-Ragan Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties J. Pharmacol. Exp. Ther. 268 1994 1297 1303
49. O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, F. Stocchi, and E. Tolosa Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial Lancet 365 2005 947 954
50. J. Schipper, M.T. Tulp, and H. Sijbesma Neurochemical profile of eltoprazine Drug Metabol. Drug Interact. 8 1990 85 114
51. P. Svenningsson, C. Rosenblad, K. Af Edholm Arvidsson, K. Wictorin, C. Keywood, B. Shankar, D.A. Lowe, A. Bjorklund, and H. Widner Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study Brain 138 2015 963 973
52. N.P. Visanji, S.H. Fox, T.H. Johnston, M.J. Millan, and J.M. Brotchie Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques J. Pharmacol. Exp. Ther. 328 2009 276 283